Register Login

Cartesian Therapeutics Inc (RNAC)

(10% Negative) CARTESIAN THERAPEUTICS, INC. (RNAC) Announces Delay in provided Development Timeline Due to Geopolitical Situation, Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Jan. 9, 2026, 1:08 p.m.

    📋 CARTESIAN THERAPEUTICS, INC. (RNAC) - Clinical Trial Update

    Filing Date: 2026-01-09

    Accepted: 2026-01-09 08:06:08

    Event Type: Clinical Trial Update

    Event Details:

    Cartesian Therapeutics Inc (RNAC) Announces Clinical Trial Update Cartesian Therapeutics Inc (RNAC) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: provided, Disclosures
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Geopolitical Situation, Pandemic-Related Challenges, Patient Enrollment, Regulatory Process
    • Collaboration: Exhibit 99.1 Disclosures
      • targeting CD20+ B cells, 3lymphoma patients receiving conventional CD19 DNA CAR-T, or 4gMG patients following infusion with DC-08. Data compare D85 to D1 for MG open label cohort (N=13). Pe ar so n R- Va lu e 0.00 0.10 0.20 0.30 0.40 0.50 0.60 0.70 0.80 0.90 1.00 T C R d iv er si ty (C lo n o ty p es /1 00 K ) Minimal change in autoreactivity Pe ar so n R- Va lu e 0.00 0.10 0.20 0.30 0.40 0.50 0.60 0.70 0.80 0.90 1.00 R = 0.887 3CD-19 CAR-T (Lymp) Pe ar so n R- Va lu e 0.00 0.10 0.20 0.30 0.40 0.50 0.60 0.70 0.80 0.90 1.00 R = 0.850 4DC-08 BCMA CAR-T (MG) R = 0.493 2Rituximab/CD-20 (MG)T cell Repertoire vs. clinical score (MG-ADL) Large change in autoreactivity TCR, T-cell receptor 35 Baseline characteristics: Patients in open-label Phase 2 SLE trial Ongoing RxPrior Rx Baseline SLEDAI- 2K SLE Duration (years) AgeSexParticipant MMF, HCQMMF8194
      • targeting two key BCMA+ cell populations involved in a spectrum of autoimmune diseases 33 Several autoimmune disease segments involve pathogenic contributions from both PCs/plasmablasts and pDCs, including rheumatology, nephrology, neurology, and others Selectively deleting PCs/plasmablasts and pDCs, if successful, may create a differentiated cell therapy platform • Descartes-08 is designed to target BCMA, a surface antigen expressed on plasma cells/plasmablasts and plasmacytoid dendritic cells PLASMA CELLS (PCs) AND PLASMABLASTS • PCs, plasmablasts and proliferating B cells targeted by Descartes-08 represent a tiny fraction of B cells • These cells are entirely responsible for secreting pathogenic autoantibodies • During autoimmunity, autoantibodies attack host tissue and drive inflammation PLASMACYTOID DENDRITIC CELLS (pDCs) • pDCs, which Descartes-08 is designed to target, are a rare subset of antigen-presenting cells • These cells secrete high levels of cytokines (i.e., type I interferons) that cause inflammation and tissue damage during many human autoimmune diseases • pDCs are increased in patients with autoimmunity (e.g., SLE) and interfere with optimal treatment PIONEERING mRNA CELL THERAPY FOR AUTOIMMUNITY PIONEERING mRNA CELL THERAPY FOR AUTOIMMUNITY34 Descartes-08 focuses the T-cell repertoire and selectively alters the autoreactome, showing clear biological activity Descartes-08 focuses the T-cell repertoire in a manner that correlates with clinical effect p=0.048 (Wilcoxon signed rank test) TCR Diversity D57 vs D1 Data show Clinical Score and TCR Sequencing TCR Diversity (Downsampled Rearrangements) in Phase 2a samples analyzed at Adaptive Biotechnologies (R06 dataset). For certain subjects where TCR sequencing sample data was unavailable, D1 data was imputed from Screen, and D57 data was imputed from D85. Samples from one re-treated patient were analyzed as indicated. P-value is provided for Wilcoxon matched-pairs signed rank test on all primary-treatment data pairs from D1 vs D57. Descartes-08 selectively alters the self-reactive branch of the antibody repertoire (i.e., autoreactome1) 1Bodansky et al., Journal of Clinical Investigation 2024

    🔬 Clinical Development Pipeline (CARTESIAN THERAPEUTICS, INC.):

    Product Type Development Stage Therapeutic Area Source
    Placebo Drug OTHER Phase PHASE3 Myasthaenia Gravis ClinicalTrials.gov
    Descartes-08 DRUG Phase PHASE2 Systemic Lupus Erythematosus (SLE) ClinicalTrials.gov
    Decartes-08 BIOLOGICAL Phase PHASE3 Myasthaenia Gravis ClinicalTrials.gov
    Descartes-15 DRUG Phase PHASE1 Refractory Multiple Myeloma ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Cartesian Therapeutics Inc
    • CIK: 0001453687
    • Ticker Symbol: RNAC
    • Period End Date: 2026-01-09
    • Document Type: 8-K

Search

News categories